Migraine and calcitonin-gene related peptide

JTMultimidia/Pexels
The U.S. Food and Drug Administration recently approved the fourth new drug to treat migraine since May 2018. It has been nearly a decade since the approval of any new migraine medicines, and for those patients in the conventional care system, these new treatments are a welcome sigh of relief. What makes each of these medications unique is that they all target calcitonin gene-related peptide (CGRP). But what about patients who are seeking a more natural solution to their migraines? By the time…